Italfarmaco
As of the edition of 20 October 2026, Italfarmaco runs 3 drugs, 2 of them marketed; it is on route A at 1 target and on route B at 0 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
The records place 6 company names in this family.
- Chemi S.p.A.: acquired in 2018; successor Italfarmaco
- Lacer S.A.: acquired in 2023; successor Italfarmaco
Drugs by status
| Status | Count |
|---|---|
| Marketed | 2 |
| Went quiet | 1 |
| Total | 3 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Riluzole | none listed | 9 |
| Givinostat | Ends 2040 (patent) | 0 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 1 target, route B at 0 targets.
| Target | Route |
|---|---|
| SSTR3 Somatostatin receptor type 3 | Route A |
All 1 row on route A or B
In the product1 company-target row on route A or B; 0 are not shown here, and no score is.
See all 1 targets where Italfarmaco needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Cancer: 10 trials led
- Blood and lymph: 9 trials led
- Bones, joints and muscles: 9 trials led